Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
VAC in HFpEF: Trends and Challenges
Author(s): Tianzong Li , Yiran Luo , Lina Zhao , et al Added: 2 months ago

Heart Failure

Imaging & Diagnostics
New Insights on HFpEF Treatment
Author(s): Giulio Balestrieri , Raul Limonta , Enrico Ponti , et al Added: 1 year ago

Guidelines & Statements

Heart Failure
HFSA 24: The EMBARK HFpEF Trial
Author(s): Added: 1 year ago
HFSA 24 - We are joined virtually by Dr Sanjiv Shah to discuss the primary results from EMBARK HFpEF (NCT04766892).EMBARK HFpEF is a phase 2a proof-of-concept study assessing the safety, tolerability and preliminary efficacy of mavacamten treatment on myosin biomarkers in patients with heart failure with preserved ejection fractions (HFpEF) and elevated NT-proBNP.Interview Questions:What is the… View more

Heart Failure
ACC.24: The STEP HFpEF DM Trial
Author(s): Mikhail Kosiborod Added: 1 year ago
ACC.24 — We are joined onsite by Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) to discuss the findings from the STEP HFpEF DM Trial (NCT04916470).The STEP HFpEF DM study aimed to investigate the effect of taking semaglutide 2.4mg once weekly in patients with heart failure with preserved ejection fraction (HFpEF) and diabetes mellitus type 2. The study looked at the impact of… View more

Heart Failure

Prevention & Chronic Conditions
THT 2025: GSN Ablation in HFpEF
Author(s): Marat Fudim Added: 11 months ago
THT Conference 2025 - Findings show catheter ablation of the right greater splanchnic nerve (GSN) in patients with heart failure with preserved ejection fraction (HFpEF) reduced estimated stressed blood volume in patients whether the ablation caused clinical benefits or not. This outcome indicates a confirmation of technical success that correlates with prior single-arm study findings.Dr Marat… View more

Heart Failure
The Role of GLP-1 in Heart Failure
Author(s): Amina Rakisheva , Anton Zatsarinnyy Added: 6 days ago

Heart Failure

Inherited and Congenital Cardiac Conditions
GLP-1RA in Different HFpEF Phenotypes
Author(s): Aleksandra Bykova , Maria Serova , Maria Chashkina , et al Added: 1 year ago

Cardiovascular Renal Metabolic

Heart Failure
HFSA 24: The HuMAIN-HFpEF Trial
Author(s): Ambarish Pandey Added: 1 year ago
HFSA 2024 - We are joined by Dr Ambarish Pandey (University of Texas Southwestern Medical Center, US) to discuss the findings from HuMAIN HFpEF, a phase 2A randomized, parallel-group, placebo-controlled study of HU6 in patients with obesity and heart failure with preserved ejection fraction (HFpEF).Interview Questions:What is the reasoning behind this study?Could you tell us about the mechanism… View more

Heart Failure

Prevention & Chronic Conditions
Benefits of Spironolactone: Win Ratio Analysis of the TOPCAT Trial
Author(s): Dung Viet Nguyen , Hoai Thi Thu Nguyen Added: 4 months ago

Heart Failure
ESC 23 Late-Breaker Discussion: The STEP HFpEF Trial
Author(s): Harriette Van Spall , Mikhail Kosiborod Added: 2 years ago
ESC 2023 – Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) to discuss the findings from the STEP HFpEF trial (NCT04788511). Around half of patients with heart failure have heart failure with preserved ejection fraction (HFpEF), and most patients with HFpEF are overweight or obese. Patients with… View more

Heart Failure

Prevention & Chronic Conditions